Pharmaceutical Technology

JULY 1, 2022

Ildong Pharmaceutical will licence a suite of Twist Bioscience's VHH antibody libraries after the two companies entered a partnership agreement. Twist's VHH libraries, used for discovering and developing antibodies for use in immuno-oncology, will be licensed by Ildong for three years for research and development works. .

Antibody 147

Antibody Development Licensing Licensing 147

Pharmaceutical Technology

OCTOBER 18, 2022

Gilead Sciences has entered an exclusive option and partnership agreement with MacroGenics for developing bispecific antibodies. MGD024 is an investigational bispecific antibody that attaches to CD123 and CD3. The post Gilead partners with MacroGenics for bispecific antibody development appeared first on Pharmaceutical Technology.

Antibody 130

Antibody Development Sales Clinical Trials 130

Pharmaceutical Technology

NOVEMBER 27, 2022

Biocytogen Pharmaceuticals and ADC Therapeutics have signed an assessment and option agreement for evaluating antibodies against three tumour targets. Under the deal, ADC Therapeutics will receive a licence from Biocytogen to evaluate the latter’s antibodies against the targets.

Antibody 130

Antibody Licensing Licensing Development 130

Pharmaceutical Technology

MAY 30, 2023

Lecanemab by Eisai Co Ltd, a monoclonal antibody therapy marketed for Alzheimer’s disease, is predicted to achieve the most significant commercial debut. Lecanemab leads the charge with projected sales of $4.67bn in 2028, 529% more than its closest competitor, Gammagard by Takeda.

Drugs 264

Drugs Sales Antibody Dermatology 264

Bio Pharma Dive

MAY 4, 2022

revenue for its coronavirus antibody, which was withdrawn from the market as omicron spread. Partnerships and profit-sharing deals helped Regeneron overcome the sudden loss of U.S.

Sales 154

Sales Antibody Marketing Drugs 154

Pharmaceutical Technology

OCTOBER 30, 2023

Helinus will receive €42m upfront and will be in line to receive up to €143m in regulatory and sales-based milestone payments.

Licensing 147

Licensing Licensing Antibody Marketing 147

Pharmaceutical Technology

DECEMBER 26, 2022

LegoChem Biosciences and Amgen have signed a multi-target research collaboration and license agreement to develop antibody-drug conjugates (ADC). The company will also be eligible for tiered royalties as a percentage of global commercial sales of the products.

Antibody 130

Antibody Development Drugs Licensing 130

pharmaphorum

OCTOBER 20, 2021

High demand for COVID-19 diagnostics driven by the delta variant has led to rocketing sales at Roche’s diagnostics division, allowing the company to raise its sales forecast for the year. Diagnostics sales rose 39% to CHF 13.3 Group sales rose 8% to CHF 46.7 Group sales rose 8% to CHF 46.7 billion ($14.4

Sales 98

Sales Antibody Vaccine Vaccination 98

Pharmaceutical Technology

SEPTEMBER 15, 2022

As a result of huge global sales of mRNA Covid-19 vaccines, the split in profits between Pfizer and BioNTech’s Comirnaty contributed towards revenues of $81.3bn and $22.4bn last year, respectively. Pfizer reaped $36.8bn from Comirnaty, the highest revenue generated from Covid-19 vaccine sales worldwide. YoY revenue growth.

Vaccine 272

Vaccine Vaccination Sales Generic Drugs 272

Pharmaceutical Technology

FEBRUARY 14, 2023

Precision oncology firm Corbus Pharmaceuticals and CSPC Megalith Biopharmaceutical have entered an exclusive licensing agreement for the latter’s new clinical stage antibody drug conjugate (ADC), CRB-701 (SYS6002). upfront payment and eligible for royalties on net sales. CSPC Megalith is a subsidiary of CSPC Pharmaceutical Group.

Antibody 130

Antibody Drugs Clinical Development Licensing 130

Pharmaceutical Technology

JUNE 28, 2022

Astellas Pharma and Sutro Biopharma have entered a global, strategic partnership and licencing agreement to discover and develop new immunostimulatory antibody-drug conjugates (iADCs). An iADC merges an antibody with a small molecule compound that elicits immunogenic cell death, and an immune-activating molecule.

Development 264

Development Antibody Immune Response Production 264

pharmaphorum

AUGUST 12, 2022

Half a million people in the UK with conditions like blood cancer that prevents them being protected from COVID-19 vaccines are facing another winter shielding, because the government has shelved plans to offer treatment with AstraZeneca’s antibody therapy Evusheld. One group of Chinese researchers has reported however that BA.4

Antibody 145

Antibody Vaccine Vaccination Drugs 145

pharmaphorum

NOVEMBER 8, 2021

A single dose of the COVID-19 monoclonal antibody therapy developing Regeneron reduced the risk of contracting the virus by around 82% for up to eight months, according to new trial data. The post One dose of Regeneron’s COVID antibody protects for eight months appeared first on. That was down from almost $2.6

Antibody 105

Antibody Vaccine Vaccination Immune Response 105

pharmaphorum

OCTOBER 25, 2021

Novartis isn’t giving up on the programme yet, as it still has other trials of canakinumab in play, but the latest failure makes prospects for the antibody in oncology look increasingly remote. The post Strike two for Novartis’ lung cancer antibody canakinumab appeared first on.

Antibody 124

Antibody Trials Branding Protein 124

pharmaphorum

DECEMBER 16, 2020

AbbVie is to begin clinical development of an antibody designed to neutralise the SARS-CoV-2 coronavirus after licensing the therapy in from Harbour BioMed and Utrecht University. AbbVie has begun a phase 1 clinical trial of the antibody, with clinical development beginning in the US and expanding into Europe.

Antibody 98

Antibody Trials Licensing Licensing 98

pharmaphorum

FEBRUARY 9, 2022

GlaxoSmithKline’s COVID-19 products – antibody drug Xevudy and a vaccine adjuvant – helped drive a 5% increase in 2021 revenues to £34 billion ($46 billion), ahead of what chief executive Emma Walmsley says will be a “landmark year” for the company. Last year, sales at the JV stabilised at £9.6 billion but have been.

Sales 105

Sales Production Vaccine Vaccination 105

Pharmaceutical Technology

MAY 8, 2023

Ei s ai and Bliss Biopharmaceutical have entered into a joint development agreement for antibody-drug conjugate (ADC), BB-1701, to treat cancers. BB-1701 comprises anti-HER2 antibody and eribulin and has a unique mechanism of action (MOA) including potent bystander effect and immunogenic cell death (ICD) activity.

Development 246

Development Antibody Clinical Trials Clinical Trials 246

Fierce Pharma

AUGUST 28, 2023

It’s a sale. Two months after Abcam launched a strategic review of the company, the British antibody research expert has revealed that it’s being bought by Danaher. Danaher Corporation is picking up all outstanding shares of Abcam for $24 apiece. Both companies’ boards unanimously approved the decision, Danaher and Abcam said Monday.

Antibody 96

Antibody Sales Research 96

pharmaphorum

AUGUST 6, 2021

billion from sales of just under 200 million doses of its COVID-19 vaccine, taking its tally since approval to around $6 billion from 302 million shots. Moderna is now predicting sales of $20 billion for 2021 as a whole from up to 1 billion doses delivered, which compares to Pfizer estimate of $33.5 Moderna made a massive $4.2

Sales 105

Sales Vaccine Vaccination Antibody 105

XTalks

SEPTEMBER 7, 2021

After a two-month long halt, federal officials have given the go-ahead to resume nationwide distribution of Eli Lilly’s COVID-19 monoclonal antibodies bamlanivimab and etesevimab. However, studies now show the COVID-19 monoclonal antibodies can work against the variant. 1 and Beta/B.1.351, 1.351, respectively). “The

Antibody 97

Antibody In-Vitro Drugs Sales 97

pharmaphorum

OCTOBER 6, 2022

Servier is already in the process of transforming itself into a much bigger player in cancer, and has just tripled its sales objectives for the category. billion respectively, as well as smaller deals such as its takeover of Danish antibody specialist Symphogen. billion and $1.8 billion, rising to €8 billion and approximately €2.4

Sales 98

Sales Drugs Branding Antibody 98

Fierce Pharma

JANUARY 31, 2024

AstraZeneca-partnered Enhertu has become a bright spot in Daiichi Sankyo’s business, and the Japanese pharma has again increased its sales projection for the HER2-directed antibody-drug conjugate.<

Sales 81

Sales Antibody Drugs 81

pharmaphorum

OCTOBER 8, 2024

billion, as analysts started to talk about a blockbuster sales opportunity for the selective myostatin inhibitor. Shares in Scholar Rock have gone into overdrive after the biotech reported positive phase 3 results with apitegromab in patients with spinal muscular atrophy (SMA), setting up regulatory filings in early 2025.The

Antibody 111

Antibody Trials Sales Marketing 111

Fierce Pharma

MAY 6, 2024

In a flurry of updates Monday, ADC Therapeutics revealed that it's selling $105 million in new shares while also touting results for antibody-drug conjugate Zynlonta from a small investigator-initi | ADC Therapeutics provided several company updates Monday, including that it's raising $105 million through a sale of common shares and pre-funded (..)

Sales 83

Sales Antibody Drugs 83

pharmaphorum

FEBRUARY 8, 2022

Pfizer reckons it will make a whopping $22 billion in sales of its oral COVID-19 antiviral Paxlovid in 2022, with another $32 billion from its BioNTech-partnered coronavirus vaccine Comirnaty. Pfizer shares actually fell in the wake of its results announcement as some analysts had been forecasting higher sales for Comirnaty this year.

Sales 98

Sales Vaccine Vaccination Antibody 98

pharmaphorum

JUNE 23, 2021

GlaxoSmithKline’s pitch to shareholders kicked off this afternoon with an optimistic view of its late-stage pipeline – including some big sales predictions for products like its respiratory syncytial virus (RSV) vaccine and new blood cancer drug Blenrep. billion takeover of Tesaro in 2019. £1 mRNA ambitions.

Sales 100

Sales Vaccine Vaccination Drugs 100

Pharmaceutical Technology

MAY 19, 2023

In a January presentation, the company shared that approvals in additional indications would allow Rinvoq and Skyrizi, a monoclonal antibody, to gain peak share in the different markets, including inflammatory bowel disease.

FDA Approval 264

FDA Approval Dermatology Sales Clinical Trials 264

Fierce Pharma

JUNE 29, 2023

Half a decade after Abcam quit its 270 million pound sterling pursuit of Horizon Discovery, the British antibody research expert has potentially found itself on the opposite end of the dealmaking t | Half a decade after Abcam quit its £270 million pursuit of Horizon Discovery, the British antibody research expert has potentially found itself on the (..)

Antibody 68

Antibody Sales Research 68

Pharmaceutical Technology

FEBRUARY 8, 2023

Despite receding sales, Comirnaty, its partnered COVID-19 vaccine with BioNTech, is still forecast to reach the analyst consensus global forecast sales of $33 billion for 2022, according to GlobalData’s Drugs Database Pharma Intelligence Center. billion on Dec 31, 2022. Merck & Co. billion to $281.3 and 31.6%, respectively.

Marketing 195

Marketing Sales Vaccine Vaccination 195

XTalks

JANUARY 3, 2025

In this blog, we delve into the recent sales data to highlight the top three best-selling eye drugs in 2023. Lets take a closer look at Eylea, Vabysmo and Lucentis the ophthalmology drugs that led the pack in recent sales figures. Related: Top 30 Drugs to Watch in 2024: Insights from 2023 Sales Data 1. billion, down from $1.50

Sales 85

Sales FDA Approval Drugs Medicine 85

BioSpace

OCTOBER 26, 2023

billion in the third quarter, a 17% increase from the same period last year, while bolstering its antibody-drug conjugate portfolio. The company’s blockbuster cancer asset Keytruda brought in more than $6.3

Sales 103

Sales Antibody Drugs 103

Pharmaceutical Technology

JANUARY 16, 2023

Ono Pharmaceutical and Monash University have entered an option and research collaboration for the discovery and development of antibodies that target G protein-coupled receptors (GPCRs). The collaboration is focused on developing anti-GPCR antibodies, which enable the creation of new treatments for autoimmune and inflammatory diseases.

Research 130

Research Antibody Sales Development 130

Pharmaceutical Technology

DECEMBER 19, 2022

With the latest development, Sanofi will licence a NK cell engager programme that acts on B7H3 from the antibody-based NK cell engager therapeutics (ANKET) platform of Innate. Under the latest licence deal, Sanofi will make an upfront payment of $26.4m (€25m) to Innate.

Development 264

Development Engineer Clinical Trials Clinical Trials 264

Pharmaceutical Technology

JULY 8, 2022

Zynlonta is a CD19-directed antibody-drug conjugate (ADC). Sobi will also make potential regulatory and sales-based milestone payments of up to nearly $330m to ADC as well as royalty payments based on net Zynlonta sales in territories of the former.

Sales 162

Sales Antibody Marketing Drugs 162

Pharmaceutical Technology

APRIL 3, 2023

BioNTech has signed exclusive licence and collaboration agreements with Duality Biologics (DualityBio) for the development of two antibody-drug conjugate (ADC) assets for solid tumours. The agreements also include the manufacturing and commercialisation of the two assets, including DB-1303 and DB-1311, across the globe.

Development 246

Development Sales Antibody Manufacturing 246

Pharmaceutical Technology

FEBRUARY 22, 2023

The patent battle between Amgen and Sanofi over their cholesterol-lowering antibodies has divided big pharma in the past months. Both drugs are monoclonal antibodies that inhibit the protein PCSK9. Since April 2020, Sanofi is responsible for Praluent outside of the US, while Regeneron handles its sale in the US.

Antibody 262

Antibody Drugs Protein Sales 262

World of DTC Marketing

APRIL 11, 2021

Both Pfizer and Moderna stand to make billions, and even though J&J said they would not make money on the first batch, they are already positioning yearly Covid Vaccine shots that could net them billions in sales. Antibody tests indicate you had a previous infection and that you may have some level of protection against the virus.

Vaccine 303

Vaccine Vaccination Clinical Trials Clinical Trials 303